ShanXi C&Y Pharmaceutical Group Co.,LTD. (SHE:300254)
China · Delayed Price · Currency is CNY 7.54
-0.14 (-1.82%)
Jul 30, 2026, 3:04 PM CST
SHE:300254 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 137.61 | 161.32 | 149.52 | 132 | 263.95 | 107.26 |
Cash & Short-Term Investments | 137.61 | 161.32 | 149.52 | 132 | 263.95 | 107.26 |
Cash Growth | 58.14% | 7.89% | 13.27% | -49.99% | 146.09% | -43.08% |
Accounts Receivable | 222.17 | 263.75 | 176.7 | 119.5 | 107.67 | 132.18 |
Other Receivables | 21.74 | 19 | 17.62 | 13.58 | 8.44 | 10.58 |
Receivables | 243.91 | 282.74 | 194.32 | 133.09 | 116.11 | 142.76 |
Inventory | 149.15 | 132.91 | 132.79 | 120.83 | 103.26 | 108.38 |
Prepaid Expenses | - | - | 2.49 | 2.49 | - | - |
Other Current Assets | 32.98 | 27.08 | 21.75 | 18.14 | 24.72 | 17.49 |
Total Current Assets | 563.64 | 604.06 | 500.87 | 406.55 | 508.03 | 375.89 |
Property, Plant & Equipment | 283.19 | 295.97 | 306.56 | 297.52 | 356.42 | 386.14 |
Long-Term Investments | 102.16 | 102.6 | 101.19 | 101.72 | 86.03 | 90.92 |
Goodwill | 311.99 | 311.99 | 311.99 | 316.25 | 320.35 | 339.93 |
Other Intangible Assets | 174.4 | 179.02 | 188.05 | 194.13 | 204.22 | 220.55 |
Long-Term Deferred Tax Assets | 29.18 | 29.48 | 27.62 | 20.17 | 10.92 | 12.11 |
Long-Term Deferred Charges | 40.4 | 48.52 | 38.42 | 19.16 | 19.88 | 15.67 |
Other Long-Term Assets | 83.46 | 70.94 | 73.03 | 77.56 | 78.57 | 85.6 |
Total Assets | 1,588 | 1,643 | 1,548 | 1,433 | 1,584 | 1,527 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Accounts Payable | 65.02 | 62.83 | 52.62 | 36.79 | 40.89 | 47.35 |
Accrued Expenses | 11.99 | 45.98 | 44.46 | 50.68 | 54.27 | 57.01 |
Short-Term Debt | 117.92 | 115.41 | 127.94 | 67.43 | 57.67 | 91.03 |
Current Portion of Long-Term Debt | 178.55 | 39.42 | 137.06 | - | 33.84 | 93.73 |
Current Portion of Leases | - | 8.24 | 8.3 | - | 1.9 | 5.85 |
Current Income Taxes Payable | 18.4 | 10.68 | 9.51 | 1.97 | 4.65 | 3.58 |
Current Unearned Revenue | 37.51 | 41.18 | 25.95 | 22.95 | 38.23 | 22.95 |
Other Current Liabilities | 143.02 | 293.45 | 164.95 | 242.54 | 368.23 | 78.53 |
Total Current Liabilities | 572.41 | 617.21 | 570.81 | 422.37 | 599.68 | 400.03 |
Long-Term Debt | 257.75 | 216 | 153.3 | 139.9 | 174.52 | 33.04 |
Long-Term Leases | 17.5 | 22.64 | 30.32 | 18.89 | 20.99 | 5.94 |
Long-Term Unearned Revenue | 16.74 | 16.95 | 17.43 | 15.32 | 15.38 | 16.16 |
Long-Term Deferred Tax Liabilities | 42.37 | 42.94 | 44.44 | 47.49 | 40.53 | 40.99 |
Other Long-Term Liabilities | 167.58 | 132.53 | 133.24 | 10.68 | 3.61 | 286.07 |
Total Liabilities | 1,074 | 1,048 | 949.55 | 654.64 | 854.7 | 782.23 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Common Stock | 256.06 | 256.11 | 248.32 | 241.62 | 241.62 | 227.97 |
Additional Paid-In Capital | 441.62 | 309.56 | 349.58 | 623.91 | 623.91 | 533.47 |
Retained Earnings | -195.01 | -198.36 | -223.21 | -265.4 | -290.59 | -172.03 |
Treasury Stock | -62.41 | -62.69 | -31.69 | - | - | - |
Total Common Equity | 440.25 | 304.62 | 343 | 600.13 | 574.94 | 589.41 |
Minority Interest | 73.82 | 289.7 | 255.18 | 178.3 | 154.77 | 155.17 |
Shareholders' Equity | 514.07 | 594.33 | 598.18 | 778.43 | 729.71 | 744.58 |
Total Liabilities & Equity | 1,588 | 1,643 | 1,548 | 1,433 | 1,584 | 1,527 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Total Debt | 571.71 | 401.72 | 456.92 | 226.22 | 288.92 | 229.59 |
Net Cash (Debt) | -434.1 | -240.4 | -307.41 | -94.21 | -24.97 | -122.33 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -1.77 | -0.98 | -1.27 | -0.39 | -0.11 | -0.54 |
Filing Date Shares Outstanding | 256.06 | 256.11 | 248.32 | 241.62 | 241.62 | 227.97 |
Total Common Shares Outstanding | 256.06 | 256.11 | 248.32 | 241.62 | 241.62 | 227.97 |
Working Capital | -8.77 | -13.15 | -69.94 | -15.82 | -91.65 | -24.14 |
Book Value Per Share | 1.72 | 1.19 | 1.38 | 2.48 | 2.38 | 2.59 |
Tangible Book Value | -46.14 | -186.39 | -157.04 | 89.75 | 50.36 | 28.93 |
Tangible Book Value Per Share | -0.18 | -0.73 | -0.63 | 0.37 | 0.21 | 0.13 |
Buildings | - | 185.53 | 210.74 | 217.38 | 230.56 | 231.09 |
Machinery | - | 365.09 | 359 | 347.77 | 384.06 | 357.17 |
Construction In Progress | - | 23.68 | 15.28 | 6.64 | 44.6 | 73.93 |